世界の医療・医薬品産業レポート

TOP  >  作用機序別レポート  >  Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - パイプラインレビュー 2018年上半期

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - パイプラインレビュー 2018年上半期
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018

レポートタイトル Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-04-10
体裁 PDF / 49 ページ
シングルユーザ価格 US$ 3,500
レポート分類 作用機序別レポート
地域 グローバル
領域 -
疾患名 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記の作用機序を標的とした治療薬パイプラインについての詳細な分析、該当作用機序についての包括的な情報、標的とする治療薬、および適応症、開発段階、作用機序(MoA)、投与方法(RoA)や分子タイプについての分析を提供します。
また、開発の歴史、最新のニュース、プレスリリースについても取り上げます。
さらに、開発中、開発中止プロジェクトの治療薬に関わる主要企業の概要も提供します。
また、該当作用機序の治療薬開発に関わる主要企業概要、開発中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
Adocia SAS
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Neurimmune Holding AG
Nordic Bioscience A/S
Prothena Corp Plc
reMYND NV
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
(insulin human + pramlintide acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(insulin lispro + pramlintide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReS-39 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-4982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
Featured News & Press Releases
May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes
Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions
Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042
May 05, 2014: reMYND’s novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models
Apr 10, 2013: Centennial Lecture features research on restoring memory and movement
Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Adocia SAS, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Neurimmune Holding AG, H1 2018
Pipeline by Nordic Bioscience A/S, H1 2018
Pipeline by Prothena Corp Plc, H1 2018
Pipeline by reMYND NV, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Loading....